InflaRx (IFRX) Current Deferred Revenue (2016 - 2018)
InflaRx (IFRX) posted Current Deferred Revenue of $13957.6 for Q3 2018, down 10.04% sequentially from $15514.8 in Q2 2018, and down 25.76% YoY from $18801.0 in Q3 2017.
InflaRx (IFRX) Current Deferred Revenue (2016 - 2018) Analysis & Trends
InflaRx has reported Current Deferred Revenue for 3 years, with the latest figure at $13957.6 in Q3 2018.
- Quarterly Current Deferred Revenue fell 25.76% year-over-year to $13957.6 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $13957.6 (down 25.76% YoY) and the FY2017 annual result came in at $16940.0, down 19.46% from the prior year.
- Current Deferred Revenue slipped to $13957.6 in Q3 2018 per IFRX's latest filing, from $15514.8 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $20514.8 in Q4 2016 and troughed at $13957.6 in Q3 2018.
- A 3-year average of $17274.8 and a median of $17430.5 in 2018 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2017 and 2018: Current Deferred Revenue dropped 13.91% in 2017, then declined 25.76% in 2018.
- Over 3 years, Current Deferred Revenue stood at $20514.8 in 2016, then dropped by 13.91% to $17661.5 in 2017, then fell by 20.97% to $13957.6 in 2018.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $13957.6, $15514.8, and $17199.5 for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 13,957.55 |
| Jun 30, 2018 | 15,514.78 |
| Mar 31, 2018 | 17,199.46 |
| Dec 31, 2017 | 17,661.49 |
| Sep 30, 2017 | 18,801.01 |
| Dec 31, 2016 | 20,514.76 |